Here the authors identify nicotine-derived inhibitors of the SARS-CoV−2 main protease that outperform Paxlovid in cells and mice, remain effective against resistant variants, and show broad activity against multiple human coronaviruses.
- Kaustav Khatua
- Sandeep Atla
- Wenshe Ray Liu
